>欧洲遗传性视网膜疾病市场，按疾病类型（视网膜色素变性、斯塔加特病、全色盲、视锥杆营养不良、脉络膜缺失、莱伯先天性黑蒙、黄斑水肿等）、类型（诊断和治疗）、最终用户（医院、专科诊所、门诊手术中心、家庭医疗保健等）、分销渠道（零售销售和直接招标）划分，行业趋势及预测至 2029 年。
市场分析和见解：欧洲遗传性视网膜疾病市场
遗传性视网膜疾病（IRD）是一组可能导致严重视力丧失甚至失明的疾病。每个 IRD 都由至少一个基因无法正常工作引起。IRD 会影响所有年龄段的人，进展速度不同，而且很少见。然而，许多 IRD 是退行性的，这意味着疾病的症状会随着时间的推移而恶化。常见的 IRD 类型包括莱伯先天性黑蒙 (LCA)、视网膜色素变性、脉络膜白斑、斯塔加特病和全色盲。基因治疗的目标是纠正或补偿有缺陷的基因。由于视网膜具有独特的物理构造，IRD 是基因治疗的强有力候选者。与身体的其他器官相比，眼睛很小，易于进行治疗。然而，身体的某些部位具有免疫特权，这意味着正常的免疫反应不那么活跃。这通常发生在我们身体非常重要的部位，如果出现肿胀或炎症，可能会受损。这意味着植入眼睛的任何东西（例如带有修正基因的细胞）都不太可能被排斥。
遗传性视网膜疾病的诊断和治疗包括各种技术，这些技术允许在产品获批后诊断遗传性视网膜疾病。该疾病的治疗方法最近获得批准，这支持了市场的增长。
遗传性视网膜疾病具有支持作用，旨在减少疾病的进展。Data Bridge Market Research 分析，遗传性视网膜疾病市场在 2022 年至 2029 年的预测期内将以 9.0% 的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制至 2019 - 2014） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
疾病类型（视网膜色素变性、斯塔加特病、全色盲、视锥细胞-视杆细胞营养不良、脉络膜缺失、莱伯先天性黑蒙、黄斑水肿等）、按类型（诊断和治疗）、最终用户（医院、专科诊所、门诊手术中心、家庭医疗保健等）、分销渠道（零售和直接招标） |
|
覆盖国家 |
Germany, France, U.K., Russia, Italy, Spain, Netherlands, Switzerland, Poland, Turkey, Austria, Hungary, Norway, Ireland, Lithuania, Rest of Europe in Europe |
|
Market Players Covered |
Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson, IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies |
Inherited Retinal Diseases Market Dynamics
Drivers
- Increase in the Prevalence of Inherited Retinal Diseases
The increasing prevalence and continuous discovery of new mutagenic sites that are genetically transmitted are expected to act as a driver for the growth of the market. The prevalence of monogenic IRDs is approximately 1 in 2000 affecting two million people online.
- Increasing in Pipeline Products
As clinical trial activity rises to new levels, the field appears poised to make rapid and important advances in IRD research and patient care. These are only a few common trials, thus, the companies operating in this market continuously do clinical trials and put their candidates in clinical trials. This is expected to create an opportunity and fuel the Europe inherited retinal diseases market.High prevalence of genetic conditions
Also, the increase in the prevalence rate of some genetic conditions such as Miller-Dieker syndrome and Walker-Warburg syndrome will further enhance the growth of inherited retinal diseases market.
Furthermore, Increase in strategic initiatives by key players, advancement in medical technology, increasing product approval for IRDs, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the inherited retinal diseases market. Other factors such as increase in the demand for effective therapies and rising adoption rate for early genetic counselling will positively impact the inherited retinal diseases market's growth rate. Additionally, high disposable income, rising number of cases of various retinal diseases will result in the expansion of inherited retinal diseases market.
Opportunities
- Invrease in Government Initiatives Towards Inherited Retinal Disease.
Moreover, the increase in awareness and treatment seeking rate and emerging reimbursement policies for the treatment will boost new opportunities for the market's growth rate.
Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the inherited retinal diseases market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate inherited retinal diseases market in future.
Restraints/Challenges
However, high cost associated with the available treatment and lack of infrastructure in low-income countries will impede the growth rate of inherited retinal diseases market. Additionally, lack of enough qualified professionals, and complications involved with the disease will hinder the inherited retinal diseases market growth.
This inherited retinal diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Inherited retinal diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Inherited retinal disease is a genetic disorder that is relatively uncommon and whose incidence is unknown. According to a study of inherited retinal diseases the prevalence of IRD’s is 1 in 3000.
Retinitis pigmentosa is the most common disorder among the other disorders. Retinitis pigmentosa is a group of related eye disorders caused by variations in 60 genes that affect the retina. IRDs are a heterogeneous group of orphan eye diseases with a prevalence estimated at between 1.0and 2.5%, with a Europe IRD caseload in the range of 5–10 million individuals.
Inherited retinal diseases market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Post COVID-19 Impact on Inherited Retinal Diseases Market
The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.
Recent Development
- In January 2022, some of the European Contries has approved the Luxturan Therapy such as Italy and also developed the reimbursement policies for the drug.
Europe Inherited Retinal Diseases Market Scope
The inherited retinal diseases market is segmented into disease type, type, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Disease Type
- Retinitis Pigmentosa
- Stargardt’s Disease
- Achromatopsia
- Cone-Rod Dystrophy
- Choroideremia
- Leber Congenital Amaurosis (LCA)
- Macular Edema
- Others
On the basis of type, the Inherited Retinal Diseasesmarket is segmented into disease type (retinitis pigmentosa, stargardt’s disease, achromatopsia, cone-rod dystrophy, choroideremia, leber congenital amaurosis, macular edema, and others
Type
- Diagnosis
- Therapy
On the basis of type, the inherited retinal diseases market is segmented into diagnosis and therapy. The diagnosis segment is sub-segmented into gene therapy, retinal prosthetic, neuroprotective agents, others. The neuroprotective agents are further sub-segmented into vitamin A palmitate, docosahexaenoic acid (DHA), lutein, others. The diagnosis segment is segmented into clinical diagnosis and genetic diagnosis. Clinical diagnosis is further sub-segmented into retinal imaging, electrophysiological tests, visual field test and clinical eye examination. Retinal imaging is further segmented into optical coherence tomography (OCT), fundus autofluorescence imaging (FAF), scanning laser ophthalmoscopy (SLO), adaptive optics (AO) imaging and conventional color fundus imaging. Electrophysiological tests are further segmented into full-field electroretinogram (ERG) and dark adaptometry (DA). Visual field test is further segmented into computerized visual field tests and manual field test. Clinical Eye examination is segmented into slit lamp, indirect ophthalmoscopy, refraction test, dilation exam
End User
- Hospitals
- Specialty Clinics
- Ambulatory surgical center
- Home Healthcare
- Others
On the basis of end-users, the inherited retinal diseases market is segmented into hospitals, specialty clinics, ambulatory surgical center, home healthcare and others
Distribution Channel
- Retail Sales
- Direct Tender
The inherited retinal diseases market is also segmented on the basis of distribution channel into retail sales, direct tender.
Pipeline Analysis
The pipeline analysis of inherited retinal diseases drugs includes various pipeline therapies such as NCT05244304, NCT00999609, NCT05176717, NCT05158296, NCT04850118. Belite Bio, Inc, Spark Therapeutics, ProQR Therapeutics, Applied Genetic Technologies Corp, Biogen, MeiraGTx Ltd are involved in the development of potential drugs for the improvement of treatment of seizures.
Inherited Retinal Diseases Market Regional Analysis/Insights
The inherited retinal diseases market is analysed and market size insights and trends are provided by country, disease type, type, end-user and distribution channel as referenced above.
The countries covered in the inherited retinal diseases market report are Germany, France, U.K., Russia, Italy, Spain, Netherlands, Switzerland, Poland, Turkey, Austria, Hungary, Norway, Ireland, Lithuania, Rest of Europe in Europe.
Germany dominates the inherited retinal diseases market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the advance technology and product approval in European region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Europe brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Inherited Retinal Diseases Market Share Analysis
The inherited retinal diseases market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on inherited retinal diseases market.
Some of the major players operating in the inherited retinal diseases market are Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson, IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies among others.
研究方法：欧洲遗传性视网膜疾病市场
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，涉及数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、欧洲与地区和供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE INHERITED RETINAL DISEASES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS FOR EUROPE INHERITED RETINAL DISEASES MARKET
5 REGULATORY FRAMEWORK
6 PREMIUM INSIGHTS
6.1 PESTEL ANALYSIS
6.2 POTER’S FIVE FORCES MODEL
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES
7.1.2 INCREASE IN PIPELINE PRODUCTS
7.1.3 INCREASING PRODUCT APPROVAL FOR INHERITED RETINAL DISEASES
7.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER
7.2 RESTRAINTS
7.2.1 HIGH COST OF TREATMENT AND PROCEDURES
7.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS
7.3 OPPORTUNITIES
7.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARDS INHERITED RETINAL DISEASES(IRDS)
7.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE
7.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT
7.4 CHALLENGES
7.4.1 RISKS ASSOCIATED WITH IRD SPECIFIC GENE THERAPY
7.4.2 LIMITED ACCESS TO TREATMENT
8 EUROPE INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE
8.1 OVERVIEW
8.2 RETINITIS PIGMENTOSA
8.3 STARGARDT’S DISEASE
8.4 ACHROMATOPSIA
8.5 CONE-ROD DYSTROPHY
8.6 CHOROIDEREMIA
8.7 LEBER CONGENITAL AMAUROSIS (LCA)
8.8 MACULAR EDEMA
8.9 OTHERS
9 EUROPE INHERITED RETINAL DISEASES MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIAGNOSIS
9.2.1 CLINICAL DIAGNOSIS
9.2.1.1 RETINAL IMAGING
9.2.1.1.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)
9.2.1.1.2 FUNDUS AUTOFLUORESCENCE IMAGING (FAF)
9.2.1.1.3 SCANNING LASER OPHTHALMOSCOPY (SLO)
9.2.1.1.4 ADAPTIVE OPTICS (AO) IMAGING
9.2.1.1.5 CONVENTIONAL COLOR FUNDUS IMAGING
9.2.1.2 ELECTROPHYSIOLOGICAL TESTS
9.2.1.2.1 FULL-FIELD ELECTRORETINOGRAM (ERG)
9.2.1.2.2 DARK ADAPTOMETRY (DA)
9.2.1.3 VISUAL FIELD TEST
9.2.1.3.1 COMPUTERIZED VISUAL FIELD TESTS
9.2.1.3.2 MANUAL FIELD TEST
9.2.1.4 CLINICAL EYE EXAMINATION
9.2.1.4.1 SLIT LAMP
9.2.1.4.2 INDIRECT OPHTHALMOSCOPY
9.2.1.4.3 REFRACTION TEST
9.2.1.4.4 DILATION EXAM
9.2.1.5 OTHERS
9.2.2 GENETIC DIAGNOSIS
9.3 THERAPY
9.3.1 GENE THERAPY
9.3.2 RETINAL PROSTHETIC
9.3.3 NEUROPROTECTIVE AGENTS
9.3.3.1 VITAMIN A PALMITATE
9.3.3.2 DOCOSAHEXAENOIC ACID
9.3.3.3 LUTEIN
9.3.3.4 OTHERS
9.3.4 OTHERS
10 EUROPE INHERITED RETINAL DISEASES MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 SPECIALTY CLINICS
10.4 AMBULATORY SURGICAL CENTERS
10.5 HOME HEALTHCARE
10.6 OTHERS
11 EUROPE INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 RETAIL SALES
11.2.1 HOSPITAL PHARMACIES
11.2.2 RETAIL PHARMACIES
11.2.3 OTHERS
11.3 DIRECT TENDER
12 EUROPE INHERITED RETINAL DISEASES MARKET, BY REGION
12.1 EUROPE
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K.
12.1.4 RUSSIA
12.1.5 ITALY
12.1.6 SPAIN
12.1.7 NETHERLANDS
12.1.8 SWITZERLAND
12.1.9 POLAND
12.1.10 TURKEY
12.1.11 AUSTRIA
12.1.12 HUNGARY
12.1.13 NORWAY
12.1.14 IRELAND
12.1.15 LITHUANIA
12.1.16 REST OF EUROPE
13 EUROPE INHERITED RETINAL DISEASES MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 SPARK THERAPEUTICS, INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 COMPANY SHARE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENTS
15.1.4.1 PROGRAM LAUNCH
15.1.4.2 ACQUISITIONS
15.2 NOVARTIS AG
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.2.5.1 AGREEMENT
15.3 OKUVISION
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.3.4.1 EXPANSION
15.3.4.2 EVENTS
15.3.4.3 APPROVAL
15.4 NIDEK CO., LTD
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENTS
15.4.4.1 PRODUCT LAUNCH
15.4.4.2 PRODUCT LAUNCH
15.5 INVITAE CORPORATION
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.5.5.1 PROGRAM LAUNCH
15.5.5.2 ACQUISITION
15.6 ZEISS INTERNATIONAL
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENTS
15.6.4.1 EVENTS
15.6.4.2 SOCIAL INVOLVEMENT
15.7 OPTOS (A SUBSIDIARY OF NIKON CORPORATION)
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENTS
15.8 NEUROSOFT
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 ASTELLAS PHARMA INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 BIONIC VISION TECHNOLOGIES
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.10.3.1 AWARD
15.11 COAVE THERAPEUTICS
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.11.3.1 AGREEMENT
15.12 GENSIGHT BIOLOGICS
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.12.4.1 EVENT
15.12.4.2 AWARD
15.13 IONIS PHARMACEUTICALS
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.13.4.1 EVENT
15.14 IVERIC BIO
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 JOHNSON &JOHNSON SERVICES, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.15.4.1 COLLABORATION
15.16 LKC TECHNOLOGIES, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.16.3.1 PRODUCT LAUNCH
15.17 MEIRAGTX LIMITED
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENTS
15.17.3.1 EVENTS
15.17.3.2 AWARD
15.17.3.3 COLLABORATION
15.18 OCUGEN INC.
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
15.18.3.1 INVESTMENT
15.18.3.2 CLINICAL TRIAL
15.19 PIXIUM VISION
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.19.4.1 AWARD
15.2 PROQR THERAPEUTICS
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.20.3.1 EVENT
15.21 SECOND SIGHT
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENT
15.21.3.1 PRODUCT LAUNCH
15.22 SPARING VISION
15.22.1 COMPANY SNAPSHOT
15.22.2 PRODUCT PORTFOLIO
15.22.3 RECENT DEVELOPMENT
15.22.3.1 ACQUISITION
15.23 REGENXBIO INC.
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENTS
15.23.3.1 EVENT
15.23.3.2 COLLABORATION
15.23.3.3 CERTIFICATION
15.24 RENEURON GROUP PLC
15.24.1 COMPANY SNAPSHOT
15.24.2 PRODUCT PORTFOLIO
15.24.3 RECENT DEVELOPMENT
15.24.3.1 STRATEGIC INITIATIVE
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 PIPELINE ANALYSIS FOR INHERITED RETINAL DISEASES:
TABLE 2 EUROPE INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 3 EUROPE RETINITIS PIGMENTOSA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE STARGARDT’S DISEASE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE ACHROMATOPSIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE CONE-ROD DYSTROPHY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE CHOROIDERMIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE LEBER CONGENITAL AMAUROSIS (LCA) IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE MACULAR EDEMA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 EUROPE DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 EUROPE CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 EUROPE RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE ELECTROPHYSIOLOGICAL TETS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 EUROPE VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 EUROPE CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 EUROPE THERAPY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 EUROPE NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 EUROPE INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 23 EUROPE HOSPITALS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE SPECIALTY CLINICS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE AMBULATORY SURGICAL CENTERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE HOME HEALTHCARE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 EUROPE INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 29 EUROPE RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 31 EUROPE DIRECT TENDER IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE INHERITED RETINAL DISEASES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 33 EUROPE INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 34 EUROPE INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 35 EUROPE THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 EUROPE NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 EUROPE DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 EUROPE CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 EUROPE RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 EUROPE ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 EUROPE VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 EUROPE CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 EUROPE INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 EUROPE INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 EUROPE RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 46 GERMANY INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 47 GERMANY INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 GERMANY THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 GERMANY NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 GERMANY DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 GERMANY CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 GERMANY RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 GERMANY ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 GERMANY VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 GERMANY CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 GERMANY INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 57 GERMANY INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 58 GERMANY RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 59 FRANCE INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 60 FRANCE INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 FRANCE THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 FRANCE NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 FRANCE DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 FRANCE CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 FRANCE RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 FRANCE ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 FRANCE VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 FRANCE CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 FRANCE INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 FRANCE INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 FRANCE RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 U.K. INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 73 U.K. INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 U.K. THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 U.K. NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 U.K. DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 U.K. CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 U.K. RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 U.K. ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 U.K. VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 U.K. CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 U.K. INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 83 U.K. INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 U.K. RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 RUSSIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 86 RUSSIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 RUSSIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 RUSSIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 RUSSIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 RUSSIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 RUSSIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 RUSSIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 RUSSIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 RUSSIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 RUSSIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 96 RUSSIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 RUSSIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 98 ITALY INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 99 ITALY INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 ITALY THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 ITALY NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 ITALY DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 ITALY CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 ITALY RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 ITALY ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 ITALY VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 ITALY CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 ITALY INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 ITALY INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 ITALY RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 111 SPAIN INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 112 SPAIN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 SPAIN THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 SPAIN NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 SPAIN DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 SPAIN CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 117 SPAIN RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 SPAIN ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 SPAIN VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 SPAIN CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 SPAIN INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 122 SPAIN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 SPAIN RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 124 NETHERLANDS INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 125 NETHERLANDS INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 NETHERLANDS THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 127 NETHERLANDS NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 NETHERLANDS DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 NETHERLANDS CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 NETHERLANDS RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 NETHERLANDS ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 NETHERLANDS VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 NETHERLANDS CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 NETHERLANDS INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 135 NETHERLANDS INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 136 NETHERLANDS RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 137 SWITZERLAND INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 138 SWITZERLAND INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 SWITZERLAND THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 140 SWITZERLAND NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 141 SWITZERLAND DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 142 SWITZERLAND CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 SWITZERLAND RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 SWITZERLAND ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 SWITZERLAND VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 SWITZERLAND CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 SWITZERLAND INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 148 SWITZERLAND INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 149 SWITZERLAND RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 150 POLAND INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 151 POLAND INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 POLAND THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 POLAND NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 154 POLAND DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 155 POLAND CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 156 POLAND RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 157 POLAND ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 POLAND VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 159 POLAND CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 POLAND INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 161 POLAND INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 162 POLAND RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 163 TURKEY INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 164 TURKEY INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 165 TURKEY THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 TURKEY NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 TURKEY DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 168 TURKEY CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 169 TURKEY RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 170 TURKEY ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 171 TURKEY VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 TURKEY CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 173 TURKEY INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 174 TURKEY INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 175 TURKEY RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 176 AUSTRIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 177 AUSTRIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 AUSTRIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 179 AUSTRIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 AUSTRIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 181 AUSTRIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 182 AUSTRIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 183 AUSTRIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 184 AUSTRIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 185 AUSTRIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 186 AUSTRIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 187 AUSTRIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 188 AUSTRIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 189 HUNGARY INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 190 HUNGARY INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 191 HUNGARY THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 HUNGARY NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 HUNGARY DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 HUNGARY CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 195 HUNGARY RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 196 HUNGARY ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 197 HUNGARY VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 HUNGARY CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 199 HUNGARY INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 200 HUNGARY INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 201 HUNGARY RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 202 NORWAY INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 203 NORWAY INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 204 NORWAY THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 205 NORWAY NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 206 NORWAY DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 207 NORWAY CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 NORWAY RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 209 NORWAY ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 NORWAY VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 211 NORWAY CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 NORWAY INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 213 NORWAY INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 214 NORWAY RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 215 IRELAND INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 216 IRELAND INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 217 IRELAND THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 218 IRELAND NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 219 IRELAND DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 220 IRELAND CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 IRELAND RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 IRELAND ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 IRELAND VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 IRELAND CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 225 IRELAND INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 226 IRELAND INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 227 IRELAND RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 228 LITHUANIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 229 LITHUANIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 LITHUANIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 231 LITHUANIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 232 LITHUANIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 233 LITHUANIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 234 LITHUANIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 235 LITHUANIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 LITHUANIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 237 LITHUANIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 238 LITHUANIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 239 LITHUANIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 240 LITHUANIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 241 REST OF EUROPE INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 EUROPE INHERITED RETINAL DISEASES MARKET: SEGMENTATION
FIGURE 2 EUROPE INHERITED RETINAL DISEASES MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE INHERITED RETINAL DISEASES MARKET: DROC ANALYSIS
FIGURE 4 EUROPE INHERITED RETINAL DISEASES MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE INHERITED RETINAL DISEASES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE INHERITED RETINAL DISEASES MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE INHERITED RETINAL DISEASES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 EUROPE INHERITED RETINAL DISEASES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE INHERITED RETINAL DISEASES MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 EUROPE INHERITED RETINAL DISEASES MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE INHERITED RETINAL DISEASES MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN EUROPE INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE EUROPE INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 RETINITIS PIGMENTOSA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE INHERITED RETINAL DISEASES MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE INHERITED RETINAL DISEASES MARKET
FIGURE 16 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2021
FIGURE 17 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2020-2029 (USD MILLION)
FIGURE 18 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 EUROPE INHERITED RETINAL DISEASES MARKET: BY TYPE, 2021
FIGURE 21 EUROPE INHERITED RETINAL DISEASES MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 22 EUROPE INHERITED RETINAL DISEASES MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 23 EUROPE INHERITED RETINAL DISEASES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 EUROPE INHERITED RETINAL DISEASES MARKET: BY END USER, 2021
FIGURE 25 EUROPE INHERITED RETINAL DISEASES MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 26 EUROPE INHERITED RETINAL DISEASES MARKET: BY END USER, CAGR (2022-2029)
FIGURE 27 EUROPE INHERITED RETINAL DISEASES MARKET: BY END USER, LIFELINE CURVE
FIGURE 28 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 29 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 30 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 31 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 32 EUROPE INHERITED RETINAL DISEASES MARKET: SNAPSHOT (2021)
FIGURE 33 EUROPE INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021)
FIGURE 34 EUROPE INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 35 EUROPE INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 36 EUROPE INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 37 EUROPE INHERITED RETINAL DISEASES MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
